Harnessing nanomaterials to induce ferroptosis in cancer treatment

Announcing a new publication for Acta Materia Medica journal. Tumor ferroptosis, a regulated form of cell death driven by iron-dependent lipid peroxidation, has emerged as a promising therapeutic strategy for combating cancers, particularly in cases involving cancer stem cells (CSCs) and drug resistance.

In recent years nanomaterial-based approaches have gained significant attention for the potential to selectively induce ferroptosis in cancer cells while sparing normal tissues. This review article aims to provide a comprehensive overview of the current state-of-the-art in utilizing nanomaterials for targeting tumor ferroptosis with a specific focus on the application in eradicating CSCs and overcoming drug resistance mechanisms. The molecular mechanisms underlying ferroptosis induction by nanomaterials, the unique properties and functionalities of various nanomaterial platforms, and strategies for targeting CSCs and overcoming drug resistance using nanoferroptosis approaches are discussed.

In addition, the preclinical and clinical evidence supporting the efficacy of nanomaterial platforms are evaluated. Furthermore, the challenges and future perspectives in the development and translation of nanoferroptosis-based therapies for precision cancer treatment are highlighted.

Source:
Journal reference:

Wang, X., et al. (2025) Ferroptosis by nanomaterials: targeting cancer stem cells and overcoming drug resistance. Acta Materia Medica. doi.org/10.15212/AMM-2024-0083.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Bispecific antibodies offer new hope for resistant NSCLC patients